SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Future studies may explore its combination with other AMPK agonists, such as berberine or SGLT2 inhibitors, to assess potential additive or synergistic therapeutic effects for multi-targeted NAFLD management.